Tianjin Medical Journal

Tianjin Medical Journal ›› 2022, Vol. 50 ›› Issue (6): 663-667.doi: 10.11958/20212432

Previous Articles     Next Articles

Effects of liraglutide combined with insulin degludec on blood glycemic variability in patients with type 2 diabetes mellitus

YAO Mingyan1, ZHANG Jing2, WANG Jie3, LI Zhihong1△, YIN Fei1   

  1. 1 Department of Endocrinology, Baoding First Central Hospital, Baoding 071000, China; 2 Department of Cardiology, Affiliated Hospital of Hebei University; 3 Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University
  • Received:2021-10-27 Revised:2022-02-08 Published:2022-06-15 Online:2023-12-20

PDF (PC)

454

Abstract: Abstract: Objective　To assess differences in the reduction of blood glucose fluctuations (GV), glucose target time (TIR) and oxidative stress levels in liraglutide plus insulin degludec and multiple daily insulin injections (MDI) using scanning glucose monitoring (FGM) system. Methods　In this randomized parallel-design study, subjects who were treated with MDI for at least one month were randomly assigned (through a computer-generated, random order) 1∶1 to either MDI treatment (control group, n=26) or liraglutide combined with insulin degludec treatment (experimental group, n=26). The primary endpoint of this study was the change in GV and TIR (3.9-10 mmol/L) from baseline to 14 days. Secondary endpoints included hypoglycemia, oxidative stress levels and body weight. Results The serum 1,5-anhydroglucitol (1,5-AG) was significantly increased in both groups (P＜0.05). After treatment, the MAGE and eHbA1c were significantly lower in the experimental group than those of the control group (P＜0.05), and 1,5-AG was significantly higher in the experimental group than that of the control group (P＜0.05). The TIR was significantly prolonged after treatment in both groups, and the time above range (TAR) (＞10 mmol/L) was significantly shortened. The time below range (TBR) (＜3.9 mmol/L) was significantly lower in the experimental group than that in the control group (P＜0.05). After treatment, 8-iso-PGF2α and 8-OHdG were significantly decreases in the experimental group than those of the control group (P＜0.05). After treatment, the body weights decreased significantly in the experimental group, while no significant changes in the control group (P＜0.05). Conclusion　Liraglutide combined with insulin degludec treatment can achieve good glycemic control in patients with type 2 diabetes and which is superior to MDI in improving GV, reducing hypoglycemia risk, oxidative stress levels and body weight.

Key words: diabetes mellitus, type 2, insulin, blood glucose, Liraglutide, insulin degludec, glycemic variability, time in range, flash glucose monitoring system